Masonic Cancer Center

A comprehensive cancer center designated by the National Cancer Institute

Transplant Biology and Therapy

About the Transplant Biology and Therapy Program

AHCMCC2 - Image - Dan Weisdorf-180x172AHCMCC2 - Image - John Wagner-180x172 Program Leaders:

John Wagner, M.D.
Daniel Weisdorf, M.D.

The Transplant Biology and Therapy Research Program has 41 members representing five departments and three schools within the Academic Health Center at the University of Minnesota.

Members of this program seek to reduce or eliminate factors limiting hematopoietic stem cell transplantation, such as regimen-related toxicities, graft-versus-host disease (GVHD), and delayed reconstitution of immunity. These scientific goals are accomplished through the development of novel treatment strategies from preclinical studies to early clinical testing in the following themes:

  • Hematopoietic reconstitution
  • Immunological reconstitution -GVHD prevention and treatment
  • Immunological reconstitution - Thymus
  • Relapse prevention and treatment
Umbilical Cord Transplantation Program
Program Meeting Schedule 
    Research Program Members
  • AHCMCC2 - Image - Afrin70x80

    Lawrence Afrin, M.D.
    Chronic myeloproliferative neoplasms, especially the mast cell activation diseases and in particular the newly recognized mast cell activation syndrome; expertise in medical informatics.

    AHCMCC2 - Image - 70x80 - Aurora Mukta

    Mukta Arora, M.D.
    Development of novel strategies for preventing chronic GVHD and identification of risk factors

    AHCMCC - Image - 70x80 - Veronika Bachanova

    Veronika Bachanova, M.D., Ph.D.
    Immune-based therapies for lymphoma and other related malignancies

    AHCMCC - Image - 70x80 - Nelli Bejanyan

    Nelli Bejanyan, M.D.
    Development of novel clinical trials for reducing the early complications of allogeneic HCT and limiting myeloid leukemia recurrence.

    AHCMCC - Image - 70x80 - Bruce Blazar

    Bruce Blazar, M.D.
    Regulation of the immune response after allogeneic HCT using murine model systems, development of immune-based therapies (e.g., use of Treg cells to modulate engraftment and GVHCO, and development of stem cell-based therapies for tissue repair after chemoradiotherapy.

    AHCMCC - Image - 70x80 - Claudio Brunstein

    Claudio Brunstein, M.D., Ph.D.
    The application of unrelated cord blood transplantation in adults; clinical trials evaluating a) complement fragment 3a (C3a) as a method for enhancing the home of UCB HSC to the hematopoietic niche, b) UCB-derived Treg as a strategy to reduce or prevent acute GVHD, and c) CTN trials exporting the use of the double UCB platform in the context of non-myeloablative conditioning

    AHCMCC2 - Image - Cichocki_70x80

    Frank Cichocki, Ph.D.
    Adaptive natural killer (NK) cell responses to viral infection and how these responses can be translated into novel therapies for hematopoietic stem cell transplantation recipients; NK cell signaling and primary immunodeficiences that impact NK cell function

    AHCMCC - Image - 70x80 - Cooley_Sarah

    Sarah Cooley, M.D.
    Development of NK cell-based immunotherapies to treat leukemia and breast cancer

    AHCMCC2 - Image 70x80 - Craig Eckfeldt

    Craig Eckfeldt, M.D., Ph.D.
    Understanding the role of RAS signaling pathways in acute myeloid leukemia (AML) to provide a foundation for the rational development of novel targeted therapies for human AML.

    AHCMCC2 - Image - Martin Felices70x80

    Martin Felices, Ph.D.
    Natural killer (NK) cell biology, with a particular interest on NK cell education, signaling, and metabolism. The ultimate goal is to manipulate these pathways to enhance NK cell survival, expansion and anti-tumor function.

    AHCMCC - Image - 70x80 - Geller_Melissa

    Mellisa Geller, M.D., M.S.
    Ovarian cancer and the treatment of uterine sarcomas, identification early in the course of treatment of the alterations in biomarker and gene profiles that will predict response to chemotherapy

    AHCMCC - Image - 70x80 - Gupta_Pankaj

    Pankaj Gupta, M.D.
    The role of proteoglycans in hematopoiesis and interactions between normal and leukemic stem cells with the microenvironment

    AHCMCC - Image - 70x80 - Hippen_Keli

    Keli Hippen, Ph.D.
    Translational development of nTreg and iTreg from adult peripheral blood and UCB, T progenitors from UCB and large scael manufacture of UCB CD19 T-CAR as a strategy for eradicating residual CD19+ malignancies

    AHCMCC2 - Image - Holtan70x80

    Shernan Holtan, M.D.
    Graft versus host disease; Immune reconstitttion post-hematopoietic cell transplant; immune-based cancer therapies; melanoma

    AHCMCC - Image - 70x80 - Susanta Hui

    Susanta Hui, Ph.D.
    Development of a radioactive calcium (41Ca) tracer for early detection of bone remodeling; development of quantitative computed tomorgraphy; quality of life of cancer survivors; anatomical image-guided conformal targeted radiation and confirmal avoidance of critical organs and real-time intra-fraction body motion tracking and  impact on targeted radiation therapy

    AHCMCC - Image - 70x80 - Jacobson_Pamala

    Pamala Jacobson, PharmD.
    Pharmacokinetics/pharacodynamics of chemotherapeutic and immunosuppressive agents for prevention of therapy-related complications

    AHCMCC2 - Image - 70x80 - Johnson L'Aurelle

    L'Aurelle Johnson, Ph.D.
    Effects of chemotherapy in cancer patients and how responses differ depending on genetics and other factors

    AHCMCC - Image - 70x80 - Kikyo_Nobuaki

    Nobuaki Kikyo, M.D., Ph.D.
    Mechanisms of nuclear reprogramming and how differentiated somatic nuclei are de-differentiated in egg cytoplasm and re-differentiated during subsequent embryogenesis

    AHCMCC2 - Image - 70x80 - Kyba Michael

    Michael Kyba, Ph.D.
    The differentiation of embryonic and induced pluirpotential stem cells into muscle and hematopoietic stem cells

    AHCMCC - Image - 70x80 - Le_Chap

    Chap Le, Ph.D.
    Data-driven and include epidemiological methods, cross-over designs, survival analysis, ordered alternatives, ROC curves, and methods for the analysis of in vitro experiments—especially chemo-combination therapy

    AHCMCC2 - Image - 70x80 - Lund Troy

    Troy Lund, M.D., Ph.D.
    Understanding the pathophysiological processes underlying metabolic storages diseases (ALD, MLD, MPSI, ETC) and improving the outcomes for metabolic storage disease hematopoietic cell transplantation using the zebrafish model; hematopoietic cell engraftment process during bone marrow transplantation and improving the efficiency and time to engraftment

    AHCMCC - Image - 70x80 - MacMillan_Margaret

    Margaret MacMillan, M.D.
    Prevention and treatment of acute GVHD; clincial trials using iTreg for prevention of acute GVHD in recipients of HLA-matched peripheral blood stem cells

    AHCMCC - Image - 70x80 - McClune_Brian

    Brian McClune, D.O.
    Clinical trials in hematologic malignancy using stem cell transplantation

    AHCMCC2 - Image - 70x80 - McCullough Jeffrey

    Jeffrey McCullough, M.D.
    Transfusion medicine as it relates to cancer and HCT patients (e.g. leukocyte infusions in sepsis, platelet alloimmunization); development of novel therapies

    AHCMCC - Image - 70x80 - McGlave_Phillip

    Phillip McGlave, M.D.
    Treatment of malignant and nonmalignant hematologic disorders including aplastic anemia, leukemia, lymphoma, multiple myeloma, myelodysplasia, and blood and marrow transplantation; experimental therapy for malignant and non-malignant hematologic disorders including stem cell transplantation, immunotherapy, and gene transfer

    AHCMCC - Image - 70x80 - McKenna_David

    David McKenna, Jr., M.D.
    Development of novel cellular therapies

    AHCMCC2 - Image - mehta_70x80

    Rohtesh Mehta, M.D., M.P.H., M.S.
    Hematological malignancies, specifically in acute leukemia, myelodysplastic syndrome and hematopoietic stem cell transplantation.

    AHCMCC - Image - 70x80 - Jeffrey Miller

    Jeffrey Miller, M.D.
    Development of immune-based therapeutics

    MEDPEDS2 - Image - 70x80 - Wes Miller

    Weston Miller, M.D.
    Development of novel clinical HCT trials in patients with metabolic disease; understanding the impact of high resolution HLA matching of UCB

    MEDPEDS2 - Image - 70x80 - Paul Orchard

    Paul Orchard, M.D.
    Development of immune-based therapeutics

    MEDPEDS2 - Image - 70x80 - Mark Osborn

    Mark Osborn, Ph.D.
    Biology of homologous recombination as a strategy for gene transfer into HSC of patients with various genetic diseases, including Fanconi anemia

    AHCMCC - Image - 70x80 - Panoskatsis-Mortari

    Angela Panoskaltsis-Mortari
    The pathophysiology of acute lung injury in the setting of allogeneic HCT and GVHD and leads studies in pulmonary regenerative medicine

    AHCMCC - Image - 70x80 - Slungaard_Arne

    Arne Slungaard, M.D.
    Inflammatory mediators of coagulation and vascular integrity with direct relevance to tumor vascularity and thrombosis in patients with cancer

    AHCMCC - Image - 70x80 - Smith_Angela

    Angela Smith, M.D., M.S.
    Early and late effects of HCT, with a focus on venoocclusive disease of the liver and infertility

    MEDPEDS2 - Image - 70x80 - Heather Stefanski

    Heather Stefanski, M.D., Ph.D.
    Thymic epithelial cell protection and expansion of T progenitors (Tprog) extrapolated from the murine model

    AHCMCC - Image - 70x80 - Tolar_Jakub

    Jakub Tolar, M.D., Ph.D.
    Development of non-hematopoietic stem cells for use in tissue repair particularly precancerous genetic diseases like epidermolysis bullosa, dykeratosis congentia and Fanconi anemia.

    AHCMCC2 - Image - 70x80 - Ustun Celalettin

    Celalettin Ustun, M.D.
    Clinical trials for acute myeloid leukemia and related myeloid malignancies

    AHCMCC2 - Image - 70x80 - Vercellotti Gregory

    Gregory Vercellotti, M.D.
    Inflammation, oxidative stress and endothelial integrity

    AHCMCC - Image - 70x80 - Verneris_Michael

    Michael Verneris, M.D.
    NK cell development and therapies; biology of immune reconstitution after allogenic BMT; clinical studies using total marrow irradiation

    AHCMCC - Image - 70x80 - John Wagner

    John Wagner, M.D.
    Development of UCB as a source of hematopoietic and non-hematopoietic stem cells for treatment of malignancy; pathophysiology of Fanconi anemia and Epidermolysis bullosa predisposition to malignancy

    AHCMCC - Image - 70x80 - Warlick_Erika

    Erica Warlick, M.D.
    The development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases

    AHCMCC - Image - 70x80 - Weigel_Brenda

    Brenda Weigel, M.D.
    Testing new pharmacological and cellular therapeutic agents in preclinical mouse models and phase 1 testing in children

    AHCMCC - Image - 70x80 - Daniel Weisdorf

    Daniel Weisdorf, M.D.
    Application of transplant therapy for acute leukemia as well as prevention and treatment of acute and chronic GVHD and late effects of HCT

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on March 29, 2016